Stablix develops targeted deubiquitination therapeutics (TDT) using small molecules to address diseases driven by aberrant ubiquitination. The company creates heterobifunctional molecules that selectively recruit deubiquitinases (DUBs) to specific target proteins to remove ubiquitin tags. This approach aims to restore normal protein stability and function for treating cancer, rare diseases, and immunological disorders.
Funding
$78M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancer, rare diseases, and immunological disorders, are driven by aberrant ubiquitination, leading to excessive protein degradation, mislocalization, or abnormal pathway activation. Targeting the ubiquitin-proteasome system (UPS) in a target-specific manner has proven challenging.
Solution
Stablix is pioneering targeted deubiquitination therapeutics (TDT) by developing heterobifunctional small molecules that selectively recruit active deubiquitinases (DUBs) to target proteins. This approach enables the precise removal of ubiquitin, restoring deficient proteins to therapeutic levels or normal function. By harnessing the body’s own cellular machinery, Stablix aims to address the underlying drivers of disease and establish a new paradigm for tackling diverse diseases. The platform aims to restore protein stability and normal function.
Target Audience
The primary target audience includes patients with rare diseases, cancer, and immunological disorders, as well as pharmaceutical companies seeking novel therapeutic modalities.
Features
- Heterobifunctional small molecules designed to selectively recruit deubiquitinases (DUBs) to target proteins.
- Targeted removal of ubiquitin to restore protein function or increase protein stability.
- Adaptable platform applicable to a range of diseases driven by aberrant ubiquitination.